Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis

Digestive Diseases and Sciences

Volumn 54, Issue 8, 2009, Pages 1693-1701

  Kovacs, Thomas O ^a   Freston, James W ^b   Haber, Marian M ^c   Hunt, Barbara ^d   Atkinson, Stuart ^d   Peura, David A ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d TAKEDA PHARMACEUTICALS   (United States)

^e UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Efficacy; Erosive esophagitis; Gastroesophageal reflux disease; GERD; Lansoprazole; Long term maintenance therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTIULCER AGENT; ATTAPULGITE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; LANSOPRAZOLE; THEOPHYLLINE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPY; EXPERIENCE; FEMALE; HEARTBURN; HUMAN; LONG TERM CARE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REFLUX ESOPHAGITIS; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG TOLERANCE; HEADACHE; LONGITUDINAL STUDY; MIDDLE AGED; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ABDOMINAL PAIN; ADULT; AGED; AGED, 80 AND OVER; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOLERANCE; ESOPHAGITIS, PEPTIC; FEMALE; HEADACHE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RECURRENCE; TREATMENT OUTCOME;

EID: 67649957818     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0769-5     Document Type: Article

References (25)

1. G Holtmann 2005 Understanding GERD symptoms in the clinical setting Drugs Today (Barc) 41 Suppl. B 13 17 10.1358/dot.2005.41.1.875775 Barc
2. G Holtmann B Adam T Liebregts 2004 Review article: the patient with gastro-esophageal reflux disease - lifestyle advice and medication Aliment Pharmacol Ther 20 Suppl. 8 24 27 10.1111/j.1365-2036.2004.02224.x (Pubitemid 39657662)
3. EA Featherstone 2005 Severe GERD: effective treatment prevents potentially serious complications JAAPA 18 25 29
4. MB Fennerty 2003 The continuum of GERD complications Cleve Clin J Med 70 Suppl. 5 S33 S50
5. JW Freston RL Jackson B Huang ED Ballard 2002 Lansoprazole for maintenance of remission of erosive esophagitis Drugs 62 1173 1184 10.2165/00003495-200262080-00004 (Pubitemid 34587571)
6. SJ Spechler 1992 Epidemiology and natural history of gastro-oesophageal reflux disease Digestion 51 Suppl. 1 24 29
7. Y Kinoshita 2004 Review article: treatment for gastro-esophageal reflux disease - lifestyle advice and medication Aliment Pharmacol Ther 20 Suppl. 8 19 23 10.1111/j.1365-2036.2004.02223.x (Pubitemid 39657661)
8. Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. 2005;CD003245.
9. SD Mathias DO Castell EP Elkin ML Matosian 1996 Health-related quality of life of patients with acute erosive reflux esophagitis Dig Dis Sci 41 2123 2129 10.1007/BF02071390 (Pubitemid 26414430)
10. CJ Mulder W Dekker M Gerretsen 1996 Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial) Dutch Study Group. Eur J Gastroenterol Hepatol 8 1101 1106 10.1097/00042737-199611000-00013 (Pubitemid 26383869)
11. JE Richter PJ Kahrilas SJ Sontag TO Kovacs B Huang JL Pencyla 2001 Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients Am J Gastroenterol 96 3089 3098 10.1111/j.1572-0241.2001.05263.x (Pubitemid 33095346)
12. DJ Hetzel J Dent WD Reed FM Narielvala M Mackinnon JH McCarthy B Mitchell BR Beveridge BH Laurence GG Gibson AK Grant DJC Shearman R Whitehead PJ Buckle 1988 Healing and relapse of severe peptic esophagitis after treatment with omeprazole Gastroenterology 95 903 912 (Pubitemid 18235531)
13. J Labenz D Armstrong K Lauritsen P Katelaris S Schmidt K Schütze G Wallner H Juergens H Preiksaitis N Keeling E Nauclér J Adler S Eklund 2005 Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive esophagitis: results from the EXPO study Aliment Pharmacol Ther 22 803 811 10.1111/j.1365-2036.2005.02643.x
14. K Lauritsen J Devière MA Bigard E Bayerdörffer G Mózsik F Murray S Kristjánsdóttir V Savarino K Vetvik D De Freitas V Orive L Rodrigo M Fried J Morris H Schneider S Eklund A Larkö 2003 Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux esophagitis: metropole study results Aliment Pharmacol Ther 17 Suppl. 1 24 27 10.1046/j.1365-2036.17.s1.7.x
15. M Robinson F Lanza D Avner M Haber 1996 Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial Ann Intern Med 124 859 867
16. SJ Sontag DG Kogut R Fleischmann DR Campbell J Richter M Haber 1996 Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The lansoprazole maintenance study group Am J Gastroenterol 91 1758 1765
17. B Thjodleifsson JA Beker C Dekkers T Bjaaland V Finnegan TJ Humphries 2000 Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease Dig Dis Sci 45 745 753 10.1023/A:1005548318996
18. GN Tytgat 2001 Review article: long-term use of proton pump inhibitors in GERD - help or hindrance? Aliment Pharmacol Ther 15 Suppl. 2 6 9 10.1046/j.1365-2036.2001.00115.x (Pubitemid 33757203)
19. F Baldi AM Morselli-Labate R Cappiello S Ghersi 2002 Italian lansoprazole study group: daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis Am J Gastroenterol 97 1357 1364 10.1111/j.1572-0241.2002.05666.x (Pubitemid 34664777)
20. L Carling C Axelsson H Forsell A Stubberöd K Kraglund U Bonnevie P Ekström 1996 Lansoprazole versus omeprazole in long term maintenance treatment of refluxoesophagitis: a Scandinavian multicentre trial Gut 39 (Suppl. 3) 182 Abstract
21. K Geboes W Dekker CJ Mulder K Nusteling 2001 Dutch study group: long-term lansoprazole treatment for gastro-esophageal reflux disease: clinical efficacy and influence on gastric mucosa Aliment Pharmacol Ther 15 1819 1826 10.1046/j.1365-2036.2001.01105.x
22. JG Hatlebakk A Berstad 1997 Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux esophagitis Aliment Pharmacol Ther 11 365 372 10.1046/j.1365-2036.1997.144320000.x (Pubitemid 27183518)
23. T Poynard JL Staub M Lemerez M Deltenre C Rekacevicz V Sallerin 1995 Efficacy and safety of lansoprazole 15 mg OAD or 30 mg OAD as one year maintenance treatment for erosive reflux esophagitis: a randomized trial Gastroenterology 108 Suppl A195 10.1016/0016-5085(95)23441-1 Abstract
24. Ip S, Bonis P, Tatsioni A, Raman G, Chew P, Kupelnick B, et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. December 2005. Available at: http://effectivehealthcare.ahrq.gov/repFiles/ GERD%20Final%20Report.pdf. Accessed 25 April 2007.
25. EJ Kuipers EC Klinkenberg-Knol SG Meuwissen 1999 Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease Yale J Biol Med 72 211 218 (Pubitemid 30215121)